Every story we've covered involving biopharmaceutical.
Novartis discontinued development of its experimental cholesterol drug after disappointing trial results, triggering a broader selloff across the biopharmaceutical sector. The failure represents a significant setback for the company and others pursuing similar strategies to reduce Lp(a), a cholesterol particle linked to cardiovascular disease.
No stories here yet.